September 2026

The GH Peptide That Survived the Crackdown

In April 2026, FDA enforcement actions against compounded GH-axis peptides knocked several familiar names off clinic menus practically overnight. CJC-1295, ipamorelin, hexarelin — compounds that had flowed through 503A compounding pharmacies for years — found themselves reclassified. One compound survived the cut: tesamorelin. Search volume is tracking at roughly 135,000 this month, a 49% increase from a year ago. The reason tesamorelin survived is simple: it has an FDA-approved drug label. The reason the surge is complicated: most of the people now seeking it don't have the condition that label was written for.

How It Works

A GHRH Analog That Works Through Your Pituitary

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends when it wants your pituitary gland to release more growth hormone. Unlike injecting GH directly, this approach works through the body's existing feedback axis. The pituitary responds, releases GH, and downstream metabolic effects follow — including the particular effect on visceral fat that the clinical trials targeted. Tesamorelin is structurally distinct from peptide secretagogues like ipamorelin, which work on the ghrelin receptor rather than the GHRH receptor. That molecular distinction ended up mattering when enforcement lines were drawn in April.

What the Trials Show

Real RCT Data, a Well-Defined Population

The clinical record here is unusually robust by peptide standards. Phase 3 randomized controlled trials in adults with HIV-associated lipodystrophy documented roughly 15–18% reductions in visceral adipose tissue compared to placebo, with effects maintained through 52-week extension phases — the trial data that earned the original FDA approval and supported the 2025 EGRIFTA WR reformulation. [PubMed indexes over 340 records](https://pubmed.ncbi.nlm.nih.gov/?term=tesamorelin) for tesamorelin, including [several meta-analyses pooling data across the HIV trial cohorts](https://pubmed.ncbi.nlm.nih.gov/?term=tesamorelin+meta-analysis). [ClinicalTrials.gov lists completed and ongoing registered studies](https://clinicaltrials.gov/search?term=tesamorelin). That evidence base is real and substantial. It's also a precise description of what was studied: a specific hormonal and metabolic disruption caused by a specific disease and its treatments.

The Off-Label Boom

The Search Numbers and the Label Tell Different Stories

One hundred thirty-five thousand monthly searches for an FDA-approved drug with a narrow, well-specified indication is a number that tells you something about the gap between the approved use case and the market for this compound. The approved indication is visceral fat reduction in adults with HIV and lipodystrophy — a real, documented condition with measurable hormonal disruption. Off-label prescribing by physicians is legal; a licensed physician can prescribe any FDA-approved drug for any use they deem medically appropriate. Tesamorelin remains available as a compounded drug through 503B outsourcing facilities under FDA's existing framework — a different legal pathway than the 503A pharmacies that lost access to GH-axis peptides last spring. What off-label prescribing doesn't do is borrow the evidentiary weight of the approved trials. The Phase 3 cohort was HIV patients. The current wave of interest is not. Whether the mechanism transfers to healthy adults pursuing body composition optimization is a plausible hypothesis. It is not a trial result.

Approved — PeptideFactCheck Stance

A Real Label Covering a Real, Narrow Indication

PeptideFactCheck rates tesamorelin Approved for the specific indication its clinical trials actually studied: visceral fat reduction in adults with HIV-associated lipodystrophy. That's a meaningful rating — tesamorelin is one of a very small number of GH-axis compounds that went through the full FDA review process, produced a reformulated version as recently as [March 2025](https://www.globenewswire.com/news-release/2025/03/25/3049233/0/en/Theratechnologies-Receives-FDA-Approval-for-EGRIFTA-WR-Tesamorelin-F8-to-Treat-Excess-Visceral-Abdominal-Fat-in-Adults-with-HIV-and-Lipodystrophy.html), and has a genuine clinical evidence trail. What the Approved rating doesn't mean: endorsement of every optimization use case the internet currently associates with this peptide. The [official drug label on DailyMed](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tesamorelin) is the document that defines what has actually been reviewed and approved. [FDA guidance on compounding](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) covers the legal landscape for availability. An approved mechanism is not an approved claim for every application of that mechanism. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.